EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Anat Yerushalmy-Feler, Elizabeth A Spencer, Suzannah Bergstein, Katarina Mitrova iD, Ondrej Hradsky, Matteo Bramuzzo iD, Magdalena Wlazlo, Christine Olbjørn, Christine Rungoe, Nathaniel Weil, Dan Turner, Shlomi Cohen iD

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izaf166 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Anat Yerushalmy-Feler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology Unit, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Heterocyclic Compounds, 3-Ring, Salvage Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on upadacitinib therapy for pediatric acute severe ulcerative colitis (ASC) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as a salvage therapy in pediatric ASC.

Methods

Children and adolescents with ASC who were treated with upadacitinib for the induction of remission were enrolled in this retrospective multicenter study. Demographic, clinical, and laboratory data as well as adverse events (AEs) were recorded after the 8-week induction period and throughout 26 weeks of therapy. Analyses were based on the intention-to-treat principal.

Results

Twenty-two patients were included (median age 15.7 [interquartile range 13.5-16.6] years, 12 hospitalized), all with anti-tumor necrosis factor (TNF) therapy refractory disease. Ten patients were treated with corticosteroids at baseline, and upadacitinib was added to an ongoing biologic therapy in five patients. At week 8 of therapy, 11 (50%) patients of the cohort remained colectomy-free and in corticosteroid-free clinical remission (CFR), and 17 (77%) patients remained colectomy-free. Normal C-reactive protein (CRP) was achieved in 9 of 11 (82%) patients who were in CFR, and fecal calprotectin <150 mcg/g in 4 of 6 (67%) patients with available data. By week 26, 14 (64%) were in CFR and 16 (73%) patients remained colectomy-free. All these patients had normal CRP levels, and 4 of 7 patients with available data had fecal calprotectin <150 mcg/g. Twelve patients reported AEs, including two serious AEs of an appendiceal neuroendocrine tumor and cytomegalovirus colitis.

Conclusion

Upadacitinib is an effective induction therapy for children and adolescents with ASC after failing anti-TNF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHeterocyclic Compounds, 3-RingSalvage TherapyHumansRetrospective StudiesFemaleMaleAdolescentRemission InductionChildSeverity of Illness IndexTreatment OutcomeColectomyAcute DiseaseFollow-Up Studies

Stichwörter der Autor:innen

JAK inhibitorsacute severe colitischildren and adolescents

Substanzen

upadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Pediatric Gastroenterology Unit, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.
  • Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
  • Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy.

ORCID-Profile: Katarina Mitrova, Matteo Bramuzzo, Shlomi Cohen

Förderung

  • NIDDK NIH HHS
  • NIH

Zitieren

APA

Yerushalmy-Feler, A., Spencer, E. A., Bergstein, S., Mitrova, K., Hradsky, O., Bramuzzo, M., Wlazlo, M., Olbjørn, C., Rungoe, C., Weil, N., Turner, D., & Cohen, S. (2025). Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf166

Vancouver

Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, et al. Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izaf166

BibTeX
@article{YerushalmyFeler2025,
  author = {Yerushalmy-Feler, Anat and Spencer, Elizabeth A and Bergstein, Suzannah and Mitrova, Katarina and Hradsky, Ondrej and Bramuzzo, Matteo and Wlazlo, Magdalena and Olbjørn, Christine and Rungoe, Christine and Weil, Nathaniel and Turner, Dan and Cohen, Shlomi},
  title = {Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izaf166}
}
Kostenlos starten →